Pancreatic cancer mRNA vaccine shows lasting results in an early trial

Key Points:

• Donna Gustafson, diagnosed with Stage 2 pancreatic cancer in early 2020, became the first patient to receive a personalized mRNA vaccine for pancreatic cancer as part of a clinical trial, shortly before mRNA vaccines for Covid-19 gained prominence.
• Pancreatic cancer is highly lethal with less than 13% five-year survival, limited screening options, and few treatment possibilities; the personalized mRNA vaccine aims to stimulate the immune system to target residual and recurring cancer cells after surgery and chemotherapy.
• In the Phase 1 trial led by Dr. Vinod Balachandran, 8 of 16 patients generated a strong immune response with T cells attacking tumor cells, and six years later, responders showed longer survival compared to non-responders, with ongoing research into the immune mechanisms involved.
• Experts caution that while results are promising, the small sample size and natural variability in pancreatic cancer outcomes mean further research and larger trials are needed; a Phase 2 trial is underway and other vaccine approaches targeting common cancer proteins like KRAS are also in development.
• The findings mark a significant shift in pancreatic cancer immunotherapy, suggesting vaccines may be more effective in early-stage disease and emphasizing the need for multiple immune-based treatments to overcome cancer resistance.